Prestige Consumer Healthcare (NYSE:PBH) Releases FY23 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) updated its FY23 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $4.18-$4.23 for the period, compared to the consensus estimate of $4.25. The company issued revenue guidance of $1.12-$1.13 billion, compared to the consensus revenue estimate of $1.11 billion.

Separately, StockNews.com began coverage on shares of Prestige Consumer Healthcare in a research report on Thursday, March 31st. They set a buy rating for the company.

Prestige Consumer Healthcare stock traded up $0.27 during trading hours on Friday, hitting $53.91. 132 shares of the stock were exchanged, compared to its average volume of 232,984. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.25 and a current ratio of 2.04. The stock has a market capitalization of $2.71 billion, a P/E ratio of 14.42, a P/E/G ratio of 1.59 and a beta of 0.58. Prestige Consumer Healthcare has a 12 month low of $44.37 and a 12 month high of $63.83. The business’s 50-day moving average is $54.88 and its two-hundred day moving average is $57.76.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.02. The firm had revenue of $266.94 million for the quarter, compared to analysts’ expectations of $258.25 million. Prestige Consumer Healthcare had a net margin of 17.85% and a return on equity of 13.90%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.79 earnings per share. On average, equities analysts predict that Prestige Consumer Healthcare will post 4.04 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $26,000. Advisor Group Holdings Inc. grew its stake in shares of Prestige Consumer Healthcare by 10.9% during the first quarter. Advisor Group Holdings Inc. now owns 3,694 shares of the company’s stock valued at $196,000 after purchasing an additional 363 shares during the last quarter. CIBC World Markets Inc. grew its stake in shares of Prestige Consumer Healthcare by 8.8% during the fourth quarter. CIBC World Markets Inc. now owns 4,387 shares of the company’s stock valued at $266,000 after purchasing an additional 353 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in shares of Prestige Consumer Healthcare by 19.7% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 6,700 shares of the company’s stock valued at $407,000 after purchasing an additional 1,105 shares during the last quarter. Finally, Oliver Luxxe Assets LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $595,000.

About Prestige Consumer Healthcare (Get Rating)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Recommended Stories